Jacqueline Boutrouille
Psychiatry · Tamarac, FLNPI 1447295886
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,400 of the $11,213 with a category attached, or 83.8%. AbbVie accounts for 87.8% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $4,900 and has fallen 98.8% since, to $58 in 2024. Among psychiatry clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 104 payments — averaging $107.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$10K
- Sunovion Pharmaceuticals Inc.$350
- Otsuka America Pharmaceutical, Inc.$333
- Alkermes, Inc.$194
- Lundbeck LLC$108
- Bausch Health US, LLC$63
- plus $317 from 10 others
What the payments were for
- Speaking & faculty fees$9,40084%
- Travel & lodging$611%
- Food & beverage$1,75216%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 37 | $9,847 |
| Sunovion Pharmaceuticals Inc. | 22 | $350 |
| Otsuka America Pharmaceutical, Inc. | 13 | $333 |
| Alkermes, Inc. | 5 | $194 |
| Lundbeck LLC | 6 | $108 |
| Bausch Health US, LLC | 4 | $63 |
| Neurocrine Biosciences, Inc. | 2 | $58 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $44 |
| Johnson & Johnson | 2 | $34 |
| Avanir Pharmaceuticals, Inc. | 2 | $32 |
| Brainsway USA Inc | 1 | $26 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Sage Therapeutics, LLC | 1 | $19 |
| Shire North American Group Inc | 1 | $17 |
| Indivior Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,213 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 23 | $42,638 |
| Lurasidone Hcl | 32 | $13,953 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 53 | $6,541 |
| Quetiapine Fumarate | 135 | $3,837 |
| Aripiprazole | 105 | $2,945 |
| Bupropion XlBupropion Hcl | 96 | $2,574 |
| Olanzapine-Fluoxetine HclOlanzapine/Fluoxetine Hcl | 11 | $2,388 |
| Duloxetine Hcl | 105 | $2,250 |
| Divalproex Sodium ErDivalproex Sodium | 13 | $1,938 |
| Olanzapine | 52 | $1,869 |
| Escitalopram Oxalate | 97 | $1,246 |
| Divalproex Sodium | 16 | $1,017 |
| Clonazepam | 239 | $1,012 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 31 | $930 |
| Fluvoxamine Maleate | 20 | $894 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $9,847 | $42,63823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Tamarac
- Rishi KakarTamarac$94K
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
- Todd BroderSt Augustine$1.6M
- Heather LuingSaint Augustine$1.5M
- Todd GatesWest Melbourne$1.2M
- Lawrence ReccoppaGainesville$968K
- Thomas ValenteLeesburg$967K
- Michelle ScargleClearwater$926K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.